Desmopressin (DDAVP) in the management of patients with congenital bleeding disorders

Haemophilia

Volumn 20, Issue 2, 2014, Pages 158-167

  Leissinger, C ^a   Carcao, M ^b   Gill, J C ^c   Journeycake, J ^d,e   Singleton, T ^a   Valentino, L ^f  

^a TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HOSPITAL FOR SICK CHILDREN   (Canada)

^c BLOOD RESEARCH INSTITUTE   (United States)

^d UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^e CHILDREN S MEDICAL CENTER   (United States)

^f RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

DDAVP; Desmopressin; Haemophilia A; Von Willebrand disease

Indexed keywords

DDAVP; DESMOPRESSIN; HAEMOPHILIA A; VON WILLEBRAND DISEASE;

BLOOD COAGULATION DISORDERS, INHERITED; DEAMINO ARGININE VASOPRESSIN; FEMALE; HEMORRHAGE; HEMOSTATICS; HUMANS; MALE; SURGICAL PROCEDURES, OPERATIVE; TREATMENT OUTCOME;

EID: 84894253433     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/hae.12254     Document Type: Review

References (61)

1. Mannucci PM, Ruggeri ZM, Pareti FI, Capitanio A. DDAVP: a new pharmacological approach to the management of hemophilia and von Willebrand disease. Lancet 1977; 1: 869-72.
2. Franchini M. The use of desmopressin as a hemostatic agent: a concise review. Am J Hematol 2007; 82: 731-5.
3. Mannucci PM, Aberg M, Nilsson IM, Robertson B. Mechanism of plasminogen activator and factor VIII increase after vasoactive drugs. Br J Haematol 1975; 30: 81-93.
4. Mannucci PM, Vicente V, Alberca I et al. Intravenous and subcutaneous administration of desmopressin (DDAVP) to hemophiliacs: pharmacokinetics and factor VIII responses. Thromb Haemost 1987; 58: 1037-9.
5. Ozgönenel B, Rajpurkar M, Lusher JM. How do you treat bleeding disorders with desmopressin? Postgrad Med J 2007; 83: 159-63.
6. Kaufmann JE, Vischer UM. Cellular mechanisms of the hemostatic effects of desmopressin (DDAVP). J Thromb Haemost 2003; 1: 682-9.
7. Leithäuser B, Zielske D, Seyfert UT, Jung F. Effects of desmopressin on platelet membrane glycoproteins and platelet aggregation in volunteers on clopidogrel. Clin Hemorheol Microcirc 2008; 39: 293-302.
8. Coppola A, Di Minno G. Desmopressin in inherited disorders of platelet dysfunction. Haemophilia 2008; 14: 31-9.
9. Cattaneo M, Lombardi R, Bettega D, Lecchi A, Mannucci PM. Shear-induced platelet aggregation is potentiated by desmopressin and inhibited by ticlopidine. Arterioscler Thromb 1993; 13: 393-7.
10. Köhler M, Harris A. Pharmacokinetics and haematological effects of desmopressin. Eur J Clin Pharmacol 1988; 35: 281-5.
11. Gill JC, Ottum M, Schwartz B. Evaluation of high dose intranasal and intravenous desmopressin in pediatric patients with mild hemophilia A and mild to moderate type 1 von Willebrand disease. J Pediatr 2002; 140: 595-9.
12. Reiter RA, Mayr F, Blazicek H et al. Desmopressin antagonizes the in vitro platelet dysfunction induced by GPIIb/IIIa inhibitors and aspirin. Blood 2003; 102: 4594-9.
13. Lethagen S, Olofsson L, Frick K, Berntorp E, Björkman S. Effect kinetics of desmopressin-induced platelet retention in healthy volunteers treated with aspirin or placebo. Haemophilia 2000; 6: 15-20.
14. Hanebutt FL, Rolf N, Loesel A, Kuhlisch E, Siegert G, Knoefler R. Evaluation of desmopressin effects on haemostasis in children with congenital bleeding disorders. Haemophilia 2008; 14: 524-30.
15. Greiff L, Andersson M, Svensson C, Lundin S, Wollmer P, Persson CG. Reduced airway absorption in seasonal allergic rhinitis. Am J Respir Crit Care Med 1997; 156: 783-6.
16. Revel-Vilk S, Schmugge M, Carcao MD, Blanchette P, Rand ML, Blanchette VS. Desmopressin (DDAVP) responsiveness in children with von Willebrand disease. J Pediatr Hematol Oncol 2003; 25: 874-9.
17. Federici AB, Mazurier C, Berntorp E et al. Biologic response to desmopressin in patients with severe type 1 and type 2 von Willebrand disease: results of a multicenter European study. Blood 2004; 103: 2032-8.
18. Castaman G, Tosetto A, Federici AB, Rodeghiero F. Bleeding tendency and efficacy of anti-haemorrhagic treatments in patients with type 1 von Willebrand disease and increased von Willebrand factor clearance. Thromb Haemost 2011; 105: 647-54.
19. Kyrle PA, Niessner H, Dent J et al. IIB von Willebrand's disease: pathogenetic and therapeutic studies. Br J Haematol 1988; 69: 55-9.
20. Seary ME, Feldman D, Carcao MD. DDAVP responsiveness in children with mild or moderate haemophilia A correlates with age, endogenous FVIII:C level and with haemophilic genotype. Haemophilia 2012; 18: 50-5.
21. Mannucci PM, Canciani MT, Rota L, Donovan BS. Response of factor VIII/von Willebrand factor to DDAVP in healthy subjects and patients with haemophilia A and von Willebrand's disease. Br J Haematol 1981; 47: 283-93.
22. de la Fuente B, Kasper CK, Rickles FR, Hoyer LW. Response of patients with mild and moderate hemophilia A and von Willebrand's disease to treatment with desmopressin. Ann Intern Med 1985; 103: 6-14.
23. Mannucci PM, Lombardi R, Castaman G et al. von Willebrand disease "Vicenza" with larger than-normal (supranormal) von Willebrand factor multimers. Blood 1988; 71: 65-70.
24. Mannucci PM, Bettega D, Cattaneo M. Patterns of development of tachyphylaxis in patients with haemophilia and von Willebrand disease after repeated doses of desmopressin (DDAVP). Br J Haematol 1992; 82: 87-93.
25. Rodeghiero F, Castaman G, Di Bona E, Ruggeri M. Consistency of responses to repeated DDAVP infusions in patients with von Willebrand's disease and hemophilia A. Blood 1989; 74: 1997-2000.
26. Casonato A, Sartori MT, de Marco L, Girolami A. 1-Desamino-8-D-arginine vasopressin (DDAVP) infusion in type IIB von Willebrand's disease: shortening of bleeding time and induction of a variable pseudothrombocytopenia. Thromb Haemost 1990; 64: 117-20.
27. McKeown LP, Connaghan G, Wilson O, Hansmann K, Merryman P, Gralnick HR. 1-Desamino-8-arginine-vasopressin corrects the hemostatic defects in type 2B von Willebrand's disease. Am J Hematol 1996; 51: 158-63.
28. Castaman G, Rodeghiero F. Desmopressin and type II B von Willebrand disease. Haemophilia 1996; 2: 73-7.
29. Mazurier C, Gaucher C, Jorieux S, Goudemand M. Biological effect of desmopressin in eight patients with type 2N ('Normandy') von Willebrand disease. Collaborative Group. Br J Haematol 1994; 88: 849-54.
30. National Heart, Lung, and Blood Institute. The Diagnosis, Evaluation, and Management of von Willebrand Disease. Bethesda, MD: US Department of Health and Human Services, 2008; Table 11: 39-40.
31. Mannucci PM. Treatment of von Willebrand's Disease. N Engl J Med 2004; 351: 683-94.
32. Mast K, Nunes M, Ruymann F, Kerlin B. Desmopressin responsiveness in children with Ehlers-Danlos syndrome associated bleeding symptoms. Br J Haematol 2008; 144: 230-3.
33. Yasui H, Adachi Y, Minami T, Ishida T, Kato Y, Imai K. Combination therapy of DDAVP and conjugated estrogens for a recurrent large subcutaneous hematoma in Ehlers-Danlos syndrome. Am J Hematol 2003; 72: 71-2.
34. Warrier AI, Lusher JM. DDAVP: a useful alternative to blood components in moderate hemophilia A and von Willebrand disease. J Pediatr 1983; 102: 228-33.
35. Mariana G, Ciavarella N, Mazzucconi MG et al. Evaluation of the effectiveness of DDAVP in surgery and bleeding episodes in hemophilia and von Willebrand's disease. A study of 43 patients. Clin Lab Haematol 1984; 6: 229-38.
36. Rodeghiero F, Castaman G, Mannucci PM. Prospective multicenter study on subcutaneous concentrated desmopressin for home treatment of patients with von Willebrand disease and mild or moderate hemophilia A. Thromb Haemost 1996; 76: 692-6.
37. Leissinger C, Becton D, Cornell C Jr, Cox Gill J. High-dose DDAVP intranasal spray (Stimate) for the prevention and treatment of bleeding in patients with mild haemophilia A, mild or moderate type 1 von Willebrand disease and symptomatic carriers of haemophilia A. Haemophilia 2001; 7: 258-66.
38. Jiménez-Yuste V, Prim MP, De Diego JI et al. Otolaryngologic surgery in children with von Willebrand disease. Arch Otolaryngol Head Neck Surg 2002; 128: 1365-8.
39. Derkay CS, Werner E, Plotnick E. Management of children with von Willebrand disease undergoing adenotonsillectomy. Am J Otolaryngol 1996; 17: 172-7.
40. Allen GC, Armfield DR, Bontempo FA, Kingsley LA, Goldstein NA, Post JC. Adenotonsillectomy in children with von Willebrand disease. Arch Otolaryngol Head Neck Surg 1999; 125: 547-51.
41. Witmer CM, Elden L, Butler RB, Manno CS, Raffini LJ. Incidence of bleeding complications in pediatric patients with type 1 von Willebrand disease undergoing adenotonsillar procedures. J Pediatr 2009; 155: 68-72.
42. Federici AB, Sacco R, Stabile F, Carpenedo M, Zingaro E, Mannucci PM. Optimising local therapy during oral surgery in patients with von Willebrand disease: effective results from a retrospective analysis of 63 cases. Haemophilia 2000; 6: 71-7.
43. Kobrinsky NL, Israels ED, Gerrard JM et al. Shortening of bleeding time by 1-deamino-8-d-arginine vasopressin in various bleeding disorders. Lancet 1984; 1: 1145-8.
44. Nitu-Whalley IC, Griffioen A, Harrington C, Lee CA. Retrospective review of the management of elective surgery with desmopressin and clotting factor concentrates in patients with von Willebrand disease. Am J Hematol 2001; 66: 280-4.
45. Kreuz W, Mentzer D, Becker S, Scharrer I, Kornhuber B. Haemate P in children with von Willebrand's disease. Haemostasis 1994; 24: 304-10.
46. James AH, Kouides PA, Abdul-Kadir R et al. Evaluation and management of acute menorrhagia in women with and without underlying bleeding disorders: consensus from an international expert panel. Eur J Obstet Gynecol Reprod Biol 2011; 158: 124-34.
47. Byams VR, Kouides PA, Kulkarni R et al.; Haemophilia Treatment Centres Network Investigators. Surveillance of female patients with inherited bleeding disorders in United States Haemophilia Treatment Centres. Haemophilia 2011; 17(Suppl. 1): 6-13.
48. Trigg DE, Stergiotou I, Peitsidis P, Kadir RA. The use of desmopressin for treatment and prophylaxis of bleeding disorders in pregnancy-a systematic review. Haemophilia 2012; 18: 25-33.
49. Ray JG. DDAVP use during pregnancy: an analysis of its safety for mother and child. Obstet Gynecol Surv 1998; 53: 450-5.
50. Burrow GN, Wassenaar W, Robertson GL, Sehl H. DDAVP treatment of diabetes insipidus during pregnancy and the postpartum period. Acta Endocrinol 1981; 97: 23-5.
51. Hale T. Medications and Mother's Milk (15th edn). Amarillo, TX: Hale Publishing, 2012: 310-1.
52. Dunn AL, Cox Gill J. Adenotonsillectomy in patients with desmopressin responsive mild bleeding disorders: a review of the literature. Haemophilia 2010; 16: 711-6.
53. Dunn AL, Powers JR, Ribeiro MJ, Rickles FR, Abshire TC. Adverse events during use of intranasal desmopressin acetate for haemophilia A and von Willebrand disease: a case report and review of 40 patients. Haemophilia 2000; 6: 11-4.
54. Weinstein RE, Bona RD, Altman AJ et al. Severe hyponatremia after repeated intravenous administration of desmopressin. Am J Hematol 1989; 32: 258-61.
55. Smith TJ, Gill JC, Ambruso DR, Hathaway WE. Hyponatremia and seizures in young children given DDAVP. Am J Hematol 1989; 31: 199-202.
56. Humphries JE. Significant hyponatremia following DDAVP administration in a healthy adult. Am J Hematol 1993; 44: 12-5.
57. Bond L, Bevan D. Myocardial infarction in a patient with hemophilia treated with DDAVP. N Engl J Med 1988; 318: 121.
58. Byrnes JJ, Larcada A, Moake JL. Thrombosis following desmopressin for uremic bleeding. Am J Hematol 1988; 28: 63-5.
59. Das P, Carcao M, Hitzler J. DDAVP-induced hyponatremia in young children. J Pediatr Hematol Oncol 2005; 27: 330-2.
60. Franchini M, Krampera M, Veneri D. Deep vein thrombosis after orthopedic surgery in a patient with type 1 von Willebrand disease and mutations in the MTHFR and beta-fibrinogen genes. Thromb Haemost 2003; 90: 963-4.
61. Leissinger C, Nugent D. Treatment and management patterns of patients with von Willebrand disease in the United States. J Blood Disord Transfus 2013. In press.